2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) All Versions of this Article: ASN.2005040423v1 16/10/3070    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kalantar-Zadeh, K. Articles by Warnock, D. G. Search for Related Content PubMed PubMed Citation Articles by Kalantar-Zadeh, K. Articles by Warnock, D. G.

Time-Dependent Associations between Iron and Mortality in Hemodialysis Patients

Kamyar Kalantar-Zadeh^*,, Deborah L. Regidor^*, Charles J. McAllister, Beckie Michael and David G. Warnock^||

^* Division of Nephrology and Hypertension, Los Angeles Biomedical Institute at Harbor-UCLA Medical Center, Torrance, California; David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California; DaVita, Inc., El Segundo, California; Division of Nephrology, Thomas Jefferson Medical College, Philadelphia, Pennsylvania; and ^|| Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama

Address correspondence to: Dr. Kamyar Kalantar-Zadeh, Division of Nephrology and Hypertension, Harbor-UCLA Medical Center, 1000 West Carson Street, Torrance, CA 90502. Phone: 310-222-3891; Fax: 310-782-1837; E-mail: kamkal{at}ucla.edu

Received for publication April 22, 2005. Accepted for publication June 20, 2005.

The independent association between the indices of iron stores or administered intravenous iron, both of which vary over time, and survival in patients who are on maintenance hemodialysis (MHD) is not clear. It was hypothesized that the observed associations between moderately high levels of three iron markers (serum ferritin, iron, and iron saturation ratio) or administered intravenous iron and all-cause and cardiovascular death is due to the time-varying confounding effect of malnutrition-inflammation-cachexia syndrome (MICS). Time-dependent Cox regression models were examined using prospectively collected data of the 2-yr (July 2001 to June 2003) historical cohort of 58,058 MHD patients from virtually all DaVita dialysis clinics in the United States. After time-dependent and multivariate adjustment for case mix, administered intravenous iron and erythropoietin doses, and available surrogates of MICS, serum ferritin levels between 200 and 1200 ng/ml (reference 100 to 199 ng/ml), serum iron levels between 60 and 120 µg/ml (reference 50 to 59 µg/ml), and iron saturation ratio between 30 and 50% (reference 45 to 50%) were associated with the lowest all-cause and cardiovascular death risks. Compared with those who did not receive intravenous iron, administered intravenous iron up to 400 mg/mo was associated with improved survival, whereas doses >400 mg/mo tended to be associated with higher death rates. The association between serum ferritin levels >800 ng/ml and mortality in MHD patients seems to be due mostly to the confounding effects of MICS. For ascertaining whether the observed associations between moderate doses of administered intravenous iron and improved survival are causal or due to selection bias by indication, clinical trials are warranted.

This article has been cited by other articles:

				C. P. Kovesdy, G. H. Lee, and K. Kalantar-Zadeh Serum Ferritin: Deceptively Simple or Simply Deceptive? Lessons Learned From Iron Therapy in Patients With Chronic Kidney Disease Journal of Pharmacy Practice, December 1, 2008; 21(6): 411 - 419. [Abstract] [PDF]

				M. Rambod, C. P. Kovesdy, and K. Kalantar-Zadeh Combined High Serum Ferritin and Low Iron Saturation in Hemodialysis Patients: The Role of Inflammation Clin. J. Am. Soc. Nephrol., November 1, 2008; 3(6): 1691 - 1701. [Abstract] [Full Text] [PDF]

				K.-L. Kuo, S.-C. Hung, Y.-H. Wei, and D.-C. Tarng Intravenous Iron Exacerbates Oxidative DNA Damage in Peripheral Blood Lymphocytes in Chronic Hemodialysis Patients J. Am. Soc. Nephrol., September 1, 2008; 19(9): 1817 - 1826. [Abstract] [Full Text] [PDF]

				T. Kapoian, N. B. O'Mara, A. K. Singh, J. Moran, A. R. Rizkala, R. Geronemus, R. C. Kopelman, N. V. Dahl, and D. W. Coyne Ferric Gluconate Reduces Epoetin Requirements in Hemodialysis Patients with Elevated Ferritin J. Am. Soc. Nephrol., February 1, 2008; 19(2): 372 - 379. [Abstract] [Full Text] [PDF]

				K. Kalantar-Zadeh, R. D. Kilpatrick, C. J. McAllister, L. G. Miller, E. S. Daar, D. W. Gjertson, J. D. Kopple, and S. Greenland Hepatitis C Virus and Death Risk in Hemodialysis Patients J. Am. Soc. Nephrol., May 1, 2007; 18(5): 1584 - 1593. [Abstract] [Full Text] [PDF]

				D. W. Coyne, T. Kapoian, W. Suki, A. K. Singh, J. E. Moran, N. V. Dahl, A. R. Rizkala, and the DRIVE Study Group Ferric Gluconate Is Highly Efficacious in Anemic Hemodialysis Patients with High Serum Ferritin and Low Transferrin Saturation: Results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study J. Am. Soc. Nephrol., March 1, 2007; 18(3): 975 - 984. [Abstract] [Full Text] [PDF]

				W. H. Horl Clinical Aspects of Iron Use in the Anemia of Kidney Disease J. Am. Soc. Nephrol., February 1, 2007; 18(2): 382 - 393. [Full Text] [PDF]

				D. H. Henry, N. V. Dahl, M. Auerbach, S. Tchekmedyian, and L. R. Laufman Intravenous Ferric Gluconate Significantly Improves Response to Epoetin Alfa Versus Oral Iron or No Iron in Anemic Patients with Cancer Receiving Chemotherapy Oncologist, February 1, 2007; 12(2): 231 - 242. [Abstract] [Full Text] [PDF]

				G. Guz, G. L. Glorieux, R. De Smet, M.-A. F. Waterloos, R. C. Vanholder, and A. W. Dhondt Impact of iron sucrose therapy on leucocyte surface molecules and reactive oxygen species in haemodialysis patients Nephrol. Dial. Transplant., October 1, 2006; 21(10): 2834 - 2840. [Abstract] [Full Text] [PDF]

				A. Besarab More than a Decade of Experience and Still No Consensus: Controversies in Iron Therapy Clin. J. Am. Soc. Nephrol., September 1, 2006; 1(Supplement_1): S1 - S3. [Full Text] [PDF]

				K. Kalantar-Zadeh, K. Kalantar-Zadeh, and G. H. Lee The Fascinating but Deceptive Ferritin: To Measure It or Not to Measure It in Chronic Kidney Disease? Clin. J. Am. Soc. Nephrol., September 1, 2006; 1(Supplement_1): S9 - S18. [Abstract] [Full Text] [PDF]

				D. L. Regidor, J. D. Kopple, C. P. Kovesdy, R. D. Kilpatrick, C. J. McAllister, J. Aronovitz, S. Greenland, and K. Kalantar-Zadeh Associations between Changes in Hemoglobin and Administered Erythropoiesis-Stimulating Agent and Survival in Hemodialysis Patients J. Am. Soc. Nephrol., April 1, 2006; 17(4): 1181 - 1191. [Abstract] [Full Text] [PDF]

				D. Y. Wu, C. S. Shinaberger, D. L. Regidor, C. J. McAllister, J. D. Kopple, and K. Kalantar-Zadeh Association between Serum Bicarbonate and Death in Hemodialysis Patients: Is It Better to Be Acidotic or Alkalotic? Clin. J. Am. Soc. Nephrol., January 1, 2006; 1(1): 70 - 78. [Abstract] [Full Text] [PDF]

				T. B. Drueke and Z. A. Massy Intravenous Iron: How Much Is Too Much? J. Am. Soc. Nephrol., October 1, 2005; 16(10): 2833 - 2835. [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673